20/03/2024 Hospitals, Clinics
Cobimetinib is classified as an MEK inhibitor, which means it works by blocking a protein called MEK that is responsible for the growth and spread of cancer cells. By inhibiting MEK, it helps to stop the growth and spread of melanoma cells, thereby slowing down the progression of the disease. The approval of Cobimetinib 20 mg in India represents a notable advancement in oncology, offering a fresh treatment choice for individuals with advanced melanoma. This medication provides a new treatment option for patients, giving them a chance to fight this aggressive form of cancer.
As a leading healthcare provider dedicated to offering cutting-edge treatments, we are proud to facilitate Cobimetinib 20 mg in India for Cancer Patients.
Cobimetinib is classified as an MEK inhibitor, which means it works by blocking a protein called MEK that is responsible for the growth and spread of ...
Venetoclax, a novel oral medication, represents a paradigm shift in cancer therapy, particularly in the realm of hematological malignancies. The effic...
Tucatinib 50 and 150 mg tablets, is transforming treatment for HER2-positive breast cancer, particularly when combined with trastuzumab and capecitabi...
Encorafenib 75 mg is a highly effective treatment for BRAF V600E-mutated cancers such as melanoma and colorectal cancer. Available across leading hosp...
More Details